Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus
- 19 April 2004
- journal article
- research article
- Published by AMPCo in The Medical Journal of Australia
- Vol. 180 (8) , 387-391
- https://doi.org/10.5694/j.1326-5377.2004.tb05991.x
Abstract
Objective: To examine whether proton‐pump inhibitor (PPI) therapy influences the incidence and progression of dysplasia in patients with Barrett's oesophagus. Design and setting: Review of prospectiv...Keywords
This publication has 24 references indexed in Scilit:
- Barrett's esophagusGastroenterology, 2002
- Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagusGastroenterology, 2002
- Barrett's-related esophageal cancer: Has the final hurdle been cleared, now paving the way for human chemoprevention trials?Gastroenterology, 2002
- The adoption of ablation therapy for Barrett's esophagus: a cohort study of gastroenterologistsAmerican Journal of Gastroenterology, 2002
- Gastroesophageal Reflux Disease and Barrett's EsophagusEndoscopy, 2002
- Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagusOncogene, 2001
- Long-Term Outcome of Antireflux Surgery in Patients With Barrett’s EsophagusAnnals of Surgery, 2001
- Barrett's-related esophageal adenocarcinoma: is chemoprevention a potential option?American Journal of Gastroenterology, 2001
- Proliferative Activity in Barrett’s Esophagus Before and After Antireflux SurgeryAnnals of Surgery, 2001
- Differentiation and proliferation in Barrett's esophagus and the effects of acid suppressionGastroenterology, 1999